Article Text

Download PDFPDF
Medical Management of the Systemic Right Ventricle
  1. Shelby Kutty1,
  2. Oktay Tutarel2,
  3. Gerhard-Paul Diller3,
  4. David A Danford1
  1. 1Division of Cardiology, University of Nebraska College of Medicine and Children’s Hospital and Medical Center, Omaha, Nebraska, USA
  2. 2Department of Paediatric Cardiology and Congenital Heart Disease, German Heart Centre Munich, Technical University of Munich, Munich, Germany
  3. 3Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, University Hospital Munich, Munich, Germany
  1. Correspondence to Dr Shelby Kutty, University of Nebraska College of Medicine and Children’s Hospital and Medical Center, Omaha, NE 68114, USA; skutty{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the Editor

We thank the correspondents for their insightful comments1  regarding the benefits of pharmacotherapy in selected patients with systemic right ventricles. The underlying principles of pharmacologic management of the systemic right ventricle are necessarily based on less than robust clinical experience, but are probably similar to those guiding management of congestive left ventricular failure. Therefore, we also use ACE inhibitors for …

View Full Text


  • Contributors All authors contributed to the response letter.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles